CTLA4 and metastatic melanoma: In patients treated for metastatic melanoma with a combination of anti–PD-1 and anti–CTLA-4 therapy, ALT increase of any grade and grade ≥3 was observed in 37 and 16% of patients, respectively (Tawbi et al., 2018).